Organization & Developments: BioMarin (Archives 2012-2017)

Parents

2012: Fiscal Year 2012 Total Revenue: $500.7 Million
2014: Repligen Announces Asset Purchase Agreement With BioMarin for HDACi Portfolio (2014)
2015: UPDATE 2-FDA panel says BioMarin DMD drug data not persuasive enough
2016: BioMarin Gene Therapy For Hemophilia Scores In Trial; Stock Jumps
2016: BioMarin Muscular Dystrophy Drug Rejected By FDA BMRN SRPT PTCT
2016: BioMarin: Pipeline Disappointments And Negative Sentiment Offer Substantial Long-Term Upside With Limited Risk - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
2016: It’s a loser: BioMarin writes off its $680M Duchenne drug gamble
2017: Biotech Forum Daily Digest: Keytruda Continues To Power Merck; Revisiting Invitae